Replies to post #672030 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

David owns 25M shares. You should stop amplifying short seller narratives.

[ilovetech]

alphapuppy - You're dealing with a narcissistic zealot. He actually suggested a poster here could get sued for defamation. In fact we had a poster here ask a very basic question, namely, "why are we seeing so many turbo cancers lately?" The inference was the mRNA vaccine I guess. The zealot's immediate response was about a video presentation by a formidable KOL in the field of genetic sequencing. Here's what the zealot's exact condensing words were:

And a “key scientist” behind this, was not a “top scientist” on the “human genome” project, I believe instead he actually was something like once a technician at a company that worked on it.

Check out Kevin Mckernan's credentials and tell me if he's "some technician." -
Kevin is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature.

Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening.

[biosectinvestor]

I am not supporting or attacking him. Your behavior is nonsensical, bizarre and has no logic and you’re attacking the orderly structure of a company in which I am invested.

I am not here to facilitate bizarre or bad behavior. And I am here only as another investor. Not here to advocate for you to be invested. If you don’t like something, you don’t have to be invested. No one is begging for you to be invested.